Download
s11764-021-01006-w.pdf 412,79KB
WeightNameValue
1000 Titel
  • Prostate cancer follow-up costs in Germany from 2000 to 2015
1000 Autor/in
  1. Michaeli, Thomas |
  2. Michaeli, Daniel |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-01
1000 Erschienen in
1000 Quellenangabe
  • 16(1):86-94
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s11764-021-01006-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881276/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The main objective of this study is to estimate and evaluate 10-year follow-up costs after prostate cancer treatment with curative (surgery, radiotherapy) and non-curative intent (hormone, androgen deprivation) per patient in Germany in 2000, 2008, and 2015.!##!Methods!#!Prostate cancer follow-up recommendations were extracted from the European Association of Urology guidelines from 2000 to 2015. Per patient costs were calculated with a detailed micro-costing approach considering direct and indirect medical expenses. Input parameters were derived from expert interviews, literature research, and official scales of tariffs. Costs for insurers, providers, and payers were included to estimate societal costs.!##!Results!#!Mean 10-year follow-up costs per patient after treatment with curative intent amounted to EUR 4415 in 2000, EUR 4224 in 2008 (p < 0.001), and EUR 5159 in 2015 (p < 0.001). Costs after hormone therapy with metastasis cumulated to EUR 10,846 in 2000, EUR 9818 in 2008 (p < 0.001), and EUR 11,978 in 2015 (p < 0.001). While insurers covered 37% of costs in 2000 (EUR 1664), only 23% of costs were reimbursed in 2015 (EUR 1195; p < 0.001). Cost sources mainly included consultations (55%), transportation (18%), and imaging (27%).!##!Conclusion!#!Early detection and advances in prostate cancer treatment increased 10-year survival rates beyond 80% in Germany, ultimately expanding the number of survivors requiring follow-up. Statutory insurers reacted by decreasing the reimbursement rates to reduce per patient cost by up to 46%. Consequently, the economic burden was mainly shifted to payers and providers.!##!Implications for cancer survivors!#!Equitable and effective follow-up schedules covered by insurance funds are necessary to care for prostate cancer patients.
1000 Sacherschließung
lokal Health insurance
lokal Follow-Up Studies [MeSH]
lokal Budget impact
lokal Humans [MeSH]
lokal Cost
lokal Article
lokal Male [MeSH]
lokal Germany [MeSH]
lokal Follow-up
lokal Androgen Antagonists [MeSH]
lokal Prostatic Neoplasms/therapy [MeSH]
lokal Health Care Costs [MeSH]
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TWljaGFlbGksIFRob21hcw==|https://orcid.org/0000-0003-2913-1867
1000 Hinweis
  • DeepGreen-ID: 6ee730050c044b68b0ed17d6016248c3 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Prostate cancer follow-up costs in Germany from 2000 to 2015
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444412.rdf
1000 Erstellt am 2023-04-27T13:07:05.372+0200
1000 Erstellt von 322
1000 beschreibt frl:6444412
1000 Zuletzt bearbeitet 2023-10-20T12:35:15.268+0200
1000 Objekt bearb. Fri Oct 20 12:35:15 CEST 2023
1000 Vgl. frl:6444412
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444412 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source